CRESUD INC. Form 6-K Summary
Business Context and Reporting Period
CRESUD INC. (CRESY), an Argentine diversified company, filed this Form 6-K on April 28, 2026, reporting a debt issuance in the local capital markets. The filing translates a letter submitted to the Comision Nacional de Valores and Bolsas y Mercados Argentinos.
Key Financial Metrics
The Company issued notes totaling approximately USD 64.2 million. Specific details for the two series are as follows:
| Note Series | Amount Issued (USD) | Interest Rate | Maturity Date | Amortization |
|---|---|---|---|---|
| Series LII | 41,201,813 | 4.75% | April 30, 2028 | Bullet at maturity |
| Series LIII | 22,998,047 | 6.25% | April 30, 2030 | Bullet at maturity |
Both series were issued at 100.00% of face value with settlement on April 30, 2026. Interest payments for both series follow a non-standard schedule: the first payment is due nine months post-issuance, the second twelve months post-issuance, and subsequent payments are semiannual in arrears.
Material Changes
This filing represents a new debt obligation. The text does not provide comparative financial data, revenue, profit, or cash flow metrics for the current or prior periods. Consequently, no material changes to operating performance can be summarized from this document.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the debt issuance. The filing does not contain specific guidance, risk factors, or contingencies beyond the terms of the notes. The unusual item noted is the irregular interest payment schedule for the first two periods (9 and 12 months) before transitioning to a standard semiannual cadence.
Investor Verification Checklist
- Verify the actual cash proceeds received versus the face value issued.
- Confirm the impact of the new debt on the Company's total leverage ratios and liquidity position.
- Review the Company's ability to service the debt given the specific interest payment dates (first payment due January 30, 2027).
- Check for any covenants or restrictions associated with the Series LII and LIII notes not detailed in this summary.